Therapeutic Asset Ratings

548 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
np137 Advanced Solid Tumor	Centre Leon Berard	P2	CCC (50)
Pyruvate Advanced Solid Tumor	National Heart Centre Singapore	P2	CCC (50)
qls31905 Advanced Solid Tumor	Qilu Pharmaceutical Co., Ltd.	P2	CCC (50)
RVU120 Advanced Solid Tumor	Ryvu Therapeutics SA	P2	CCC (50)
Sacituzumab Tirumotecan Advanced Solid Tumor	Convalife (Shanghai) Co., Ltd.	P2	CCC (50)
Shr-4602 Advanced Solid Tumor	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CCC (50)
zg005 Advanced Solid Tumor	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P2	CCC (50)
anv419 Advanced Solid Tumor	Anaveon AG	P1/2	CCC (49)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Advanced Solid Tumor	EMD Serono Research & Development Institute, Inc.	P3	CCC (48)
ag-120 Advanced Solid Tumor	Jason J. Luke, MD	P2	CCC (48)
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 Advanced Solid Tumor	Janssen Research & Development, LLC	P2	CCC (48)
prt3789 Advanced Solid Tumor	Prelude Therapeutics	P2	CCC (48)
Shr-1802 Advanced Solid Tumor	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CCC (48)
Slc-3010 Advanced Solid Tumor	Yonsei University	P2	CCC (48)
APG 115 Advanced Solid Tumor	Ascentage Pharma Group Inc.	P1/2	CCC (48)
bat1006 Advanced Solid Tumor	Bio-Thera Solutions	P1/2	CCC (48)
bat4706 Advanced Solid Tumor	Bio-Thera Solutions	P1/2	CCC (48)
Capmatinib Advanced Solid Tumor	Cancer Research UK	P2/3	CCC (48)
ECUBECTEDIN Advanced Solid Tumor	Grupo Espanol de Investigacion en Sarcomas	P1/2	CCC (48)
Jskn003 Advanced Solid Tumor	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P1/2	CCC (48)
Shr-A1921 Advanced Solid Tumor	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CCC (48)
TEGAFUR Advanced Solid Tumor	University of Malaya	P2/3	CCC (48)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Advanced Solid Tumor	BOE Technology Group Co., Ltd.	P1/2	CC (47)
5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE Advanced Solid Tumor	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (46)
Amivantamab-Vmjw Advanced Solid Tumor	Vall d'Hebron Institute of Oncology	P2	CC (46)

Showing 51 to 75 of 548 assets

PreviousPage 3 of 22Next